M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery Pharmaceutical Business ReviewUnder the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaceutical Business Review Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Roche’s KRAS drug tops its rivals in lung cancer trial Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal pharminent July 20, 2026
